Skip to main content

Market Overview

Bristol Myers Wins Positive Opinion From EU For Opdivo/Yervoy Combo In Colorectal Cancer

Share:
Bristol Myers Wins Positive Opinion From EU For Opdivo/Yervoy Combo In Colorectal Cancer
  • The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Bristol Myers Squibb & Co's (NYSE: BMY) Opdivo (nivolumab) in combination with Yervoy (ipilimumab), a subset of metastatic colorectal cancer (mCRC).
  • The recommendation covers the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) mCRC after prior fluoropyrimidine-based combination chemotherapy.
  • The opinion was based on data from the Phase 2 CheckMate -142 trial.
  • Price Action: BMY shares closed at $67.05 on Friday.
 

Related Articles (BMY)

View Comments and Join the Discussion!

Posted-In: Briefs colorectal cancer european medical agencyBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com